Stemline gives in-licenses global rights to SL-1001
Stemline Therapeutics, Inc. is a biopharmaceutical company focused on development and commercialization of novel oncology therapeutics, has licensed worldwide rights to a preclinical molecule RET (rearranged during transfection) kinase inhibitor. The RET kinase genetic mutations are found in a wide range of cancers and are prime targets in most of them. The Compound- SL-1001, designed by the scientists at Cancer Research UK Manchester Institute at the University of Manchester (United Kingdom), has shown its potential in targeting the RET molecule showing its anti-cancer nature.
HIV injectable treatment a huge relief to patients
In a very first, an injectable drug for HIV proves to be as effective as the pills. The injection suppressed the Virus expression over 90% in an effective manner. It will also provide relief to patients from taking regular oral pills. The Phase III trials conducted by Viiv Healthcare in association with Johnson & Johnson’s Edurant.
FDA approves a biosimilar to HERCEPTIN
The U.S Food and Drug Administration has approved Pfizer’s biosimilar to Roche’s Herceptin for Breast Cancer treatment. Earlier, Herzuma manufactured by South Korean manufacturer Cellitrion and Israel’s Teva pharmaceutical industries, got FDA’s approval as well.
Specific kind of electrical brain stimulation to treat Depression
UNC School of Medicine researchers in their recent experiment showed with the help of weak alternating electrical current passed via electrodes can help stimulate Brain signals thus targeting Depression. Over 70% of people subjected Transcranial alternating current stimulation (tACS) reported a 50% reduction in depression symptoms.
An OK to Roche’s Immunotherapy for TNBC by FDA
FDA approved Roche’s first immunotherapy to target metastatic breast cancer. Tecentriq in combination with older chemotherapy called Abraxane will benefit patients affected with triple-negative breast cancer (TNBC). However, the approval is further subjected to confirm the positive results.